Objective: To establishment and evaluated a new method named five-disk agar diffusion method which can test ESBLs and AmpC of Enterobacter cloacae (E. cloacae) at the same time. The regular clinical methods, four-disk test which detect the AmpC and the double-disk synergy test which detect the ESBLs were compared. Methods: Strains of E. cloacae were isolated and identified by automatic microbe system VITEK; ESBLs and AmpC enzyme were determined by five-disk agar diffusion method, four-disk test and double-disk synergy test, respectively. Results: In 33 strains of E. cloacae, there were 12 (36.4%) strains produced ESBLs, 3 (9.1%) strains produced AmpC, and 7 (21.2%) strains produced both ESBLs and AmpC enzymes by five-disk test. There were 9 (27.3%) strains produced AmpC enzyme by four-disk test. Besides, there were 20 (60.6%) strains produced ESBLs by double-disk synergy test. Compared with four-disk test and double-disk synergy test, the coincidence rates of five-disk synchronous test were 90% and 95% respectively. Identification and routine antibiograms of the isolates were carried out using the Vitek 2 automated system (BioMerieux ® , Marcy I'Etolie, France). Minimum inhibitory concentrations (MICs) of daptomycin was determinated by the agar dilution method according to Clinical Laboratory Standards Institute (CLSI) guidelines. Results: All strains tested of S. aureus and S. epidermidis were susceptible to daptomycin (MICs ≤ 1 μg/mL) as well as all strains of E. faecium and E. faecalis (MICs ≤ 4 μg/mL). At established CLSI breakpoints for vancomycin (4 μg/mL) 100% respectively, of the all strains isolates was susceptible. At established CLSI breakpoints for tigecycline (1 μg/mL), 98% of the S. aureus, 99% of the S. epidermidis and 98% of the E. faecium and E. faecalis were susceptible. MICs were ranging between 0.03-1 for S. aureus, 0.01-1 for S. epidermidis, 0.25-4 for E. faecalis and 0.5-4 for E. faecium, respectively. Conclusions: The excellent in vitro bactericidal activity of daptomycin presents the potential role of treatment of severe infections due to these bacteria. This study analysed the genetic and phenotypic cross drug resistance of harboring resistant viruses from therapy failure AIDS patients in order to better design anti-HIV-1 regimens for future treatment of HIV/AIDS patients in China. 65 AIDS patients (49 for D4T/DDI/NVP treatment; 16 for AZT/ DDI/NVP treatment) were recruited and the drug resistance was analysed using plasma RNA extract,RT-PCR and sequence. HIV viruses were further isolated from the patients' PBMC and used for phenotypic drug resistance by an in vitro susceptibility drug test. All the patients were infected by HIV-1B' subtype and harbored drug resistance to HIV-1 nucleoside reverse transcriptase (RT) inhibitors, in which 98% is NVP, 51% is AZT, 60% is D4T, 57% is DDI. In these HIV-1 viruses harboring resistant strains, there are 100% cross drug resistance to EFV, 92% to DLV, 77% to TDF, 42% to 3TC, 42% to FTC, and 84% to ABC in these therapy regimen without ABC, 3TC, FTC, TDF, EFV and DLV. Phenotypic drug resistance showed that the accordance rate between genotypic drug resistance and phenotypic drug resistance in high and intermediate drug resistance of 3TC, FTC, EFV and ABC is 72%, 78%, 94% and 89% respectively. There is cross-drug resistance to HIV-1 nucleoside reverse transcriptase (RT) inhibitors of Chinese AIDS Patients harboring resistant strains especially EFV and then ABC, FTC and 3TC. This information will help to rationally design more efficient anti-HIV-1 regimens for future treatment of HIV/AIDS patients in China. 
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Conclusions:
Almost a third of all adolescents and nearly a quarter of those under 18 met criteria for HAART initiation at first visit. Surprisingly, these young, presumably newly infected individuals meet criteria for anti-retroviral therapy early in disease. Efforts to identify HIV-infected adolescents must be intensified at all ages
